EGFR and colonic neoplasm: In this regard, considering the oncogenic mutational statuses of KRAS and BRAF harbored in colon cancer cell lines with confirmed responsiveness to rTBL-1 (Table 1), a therapeutic approach based on blocking or inhibiting EGFR would be an ineffective strategy, since in such models, the signaling is transduced even in the absence of any upstream signals.